Lynn Kamerlin, Bas de Bruin and their colleagues have been the most vocal critics of Plan S from the very beginning, braving continuous opposition from certain OA leaders. Now that final Plan S guidelines were released, the chemists publish this Open Letter expressing their worry about a possible dystopian OA future.
A new Open Letter against Plan S appeared on the internet. Presently over 600 scientists are protesting against what they see as a bit totalitarian Open Access initiative by Robert-Jan Smits and his partners from Science Europe. Among the Open Letter signatories are many early career researchers and tenured academics, including two Nobelists.
I obtained a near-verbatim transcript of a video-conference Plan S architects Robert-Jan Smits and Science Europe president Marc Schiltz had on October 19th with Lynn Kamerin and other authors of the Appeal. It appears that Smits and Schiltz see the scientists and their scholarly societies as the reactionary elements blocking the road to the universal Open Access (OA).
A “defamation Complaint” was lodged with Google, against 6 of my articles and one cartoon. Each of them affects to some degree the British laryngologist Martin Birchall, professor at UCL and former close associate of scandal surgeon Paolo Macchiarini. I also show that Birchall and UCL even now continue researching plastic tracheas on pigs, for future use in humans patients. This grant is presently funded by UK government.
David Latchman, Master of Birkbeck and professor of genetics at UCL was once again cleared of all suspicions of research misconduct, while his two subordinates took all the blame, for just 7 papers. Over 40 flagged for suspected data manipulations were ignored. Latchman is namely also Chair of the over £100 Million-heavy Maurice Wohl Charitable Foundation, which gave Birkbeck over £ 5mn.
Swedish start-up Verigraft received €2.2 Million from European Union, to further develop regenerative medicine technology tainted by research misconduct and patient abuse. The founder of this very company: Suchitra Sumitran-Holgersson. A clinical trial is scheduled based on debunked science of recellurising dead blood vessel grafts.